Access the full text.
Sign up today, get DeepDyve free for 14 days.
RG Maki, JK Wathen, SR Patel (2007)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002J Clin Oncol, 25
K Antman, J Crowley, SP Balcerzak (1993)
Randomized comparison of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue sarcomasJ Clin Oncol, 11
K. Khanfir, L. Alzieu, P. Terrier, C. Péchoux, S. Bonvalot, D. Vanel, A. Cesne (2003)
Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities?European journal of cancer, 39 13
M. Christie-Large, Steven James, L. Tiessen, A. Davies, R. Grimer (2008)
Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas.European journal of cancer, 44 13
J. Edmonson, L. Ryan, R. Blum, J. Brooks, M. Shiraki, S. Frytak, D. Parkinson (1993)
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 7
S. Stacchiotti, E. Tamborini, A. Marrari, S. Brich, Sara Rota, M. Orsenigo, F. Crippa, C. Morosi, A. Gronchi, M. Pierotti, P. Casali, S. Pilotti (2009)
Response to Sunitinib Malate in Advanced Alveolar Soft Part SarcomaClinical Cancer Research, 15
William Kraybill, Jonathon Harris, Ira Spiro, D. Ettinger, Thomas Delaney, R. Blum, David Lucas, David Harmon, G. Letson, B. Eisenberg (2006)
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 4
WG Kraybill, J Harris, IJ Spiro (2006)
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high risk, high grade, soft tissue sarcomas of the extremities and body wallJ Clin Oncol, 24
J. Cormier, Shreyaskumar Patel, C. Herzog, M. Ballo, M. Burgess, B. Feig, K. Hunt, R. Raney, G. Zagars, R. Benjamin, P. Pisters (2001)
Concurrent ifosfamide‐based chemotherapy and irradiationCancer, 92
(Christie-Large M, James SL, Tiessen L, Davies AM, Grimer RJ. Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer. 2008;44(13):1841–5.)
Christie-Large M, James SL, Tiessen L, Davies AM, Grimer RJ. Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer. 2008;44(13):1841–5.Christie-Large M, James SL, Tiessen L, Davies AM, Grimer RJ. Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer. 2008;44(13):1841–5., Christie-Large M, James SL, Tiessen L, Davies AM, Grimer RJ. Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer. 2008;44(13):1841–5.
E. Stoeckle, J. Coindre, G. Kantor, L. Thomas, A. Avril, P. Lagarde, M. Kind, B. Bui (2005)
Quality of surgery in soft tissue sarcoma: a single centre experience with the French Sarcoma Group (FSG) surgical system
C. Trovik, H. Bauer, T. Alvegård, H. Anderson, Carl Blomqvist, Ö. Berlin, P. Gustafson, G. Saeter, A. Wallöe (2000)
Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register.European journal of cancer, 36 6
P. Woll, P. Reichardt, A. Cesne, S. Bonvalot, A. Azzarelli, H. Hoekstra, M. Leahy, F. Coevorden, J. Verweij, P. Hogendoorn, M. Ouali, S. Marréaud, V. Bramwell, P. Hohenberger (2012)
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.The Lancet. Oncology, 13 10
J. Butrynski, D. D’Adamo, J. Hornick, P. Cin, C. Antonescu, S. Jhanwar, M. Ladanyi, M. Capelletti, S. Rodig, N. Ramaiya, E. Kwak, Jeffrey Clark, K. Wilner, J. Christensen, P. Jänne, R. Maki, G. Demetri, G. Shapiro (2010)
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.The New England journal of medicine, 363 18
(2009)
Ann Surg
A. Cesne, A. Yovine, J. Blay, S. Delaloge, R. Maki, J. Misset, P. Frontelo, A. Nieto, J. Jiao, G. Demetri (2012)
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trialsInvestigational New Drugs, 30
R. Issels, S. Abdel-Rahman, C. Wendtner, M. Falk, V. Kurze, Hansjorg Sauer, U. Aydemir, Wolfgang Hiddemann (2001)
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.European journal of cancer, 37 13
(2015)
Local treatment for primary soft tissue sarcoma of the extremities and chest wall
S. Blackmon, Nipam Shah, J. Roth, A. Correa, A. Vaporciyan, D. Rice, W. Hofstetter, G. Walsh, R. Benjamin, R. Pollock, S. Swisher, R. Mehran (2009)
Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival.The Annals of thoracic surgery, 88 3
(Woll PJ, Reichardt P, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.)
Woll PJ, Reichardt P, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.Woll PJ, Reichardt P, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54., Woll PJ, Reichardt P, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
RD Issels, S Abdel-Rahman, C Wendtner (2001)
Neoadjuvant combined with regional hypertermia for locally advanced primary or recurrent high risk adult soft tissue sarcomas of adults: long term results of phase II studyEur J Cancer, 37
G. Zagars, M. Ballo, P. Pisters, R. Pollock, Shreyaskumar Patel, R. Benjamin (2003)
Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy.International journal of radiation oncology, biology, physics, 57 3
Walter Lawrence, William Donegan, Nachimuthu Natarajan, Curtis Mettlin, R. Beart, David Winchester (1987)
Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons.Annals of Surgery, 205
A. Oosterom, Henning Mouridsen, O. Nielsen, P. Dombernowsky, Krzysztof Krzemieniecki, I. Judson, L. Svancárová, David Spooner, Cédric Hermans, M. Glabbeke, J. Verweij (2002)
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.European journal of cancer, 38 18
B. O'Sullivan, A. Griffin, C. Dickie, M. Sharpe, P. Chung, C. Catton, P. Ferguson, J. Wunder, B. Deheshi, L. White, R. Kandel, D. Jaffray, R. Bell (2013)
Phase 2 study of preoperative image‐guided intensity‐modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcomaCancer, 119
N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer, A. Figueredo, M. Ghert (2008)
A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcomaCancer, 113
O. Cahlon, M. Brennan, X. Jia, L. Qin, S. Singer, K. Alektiar (2012)
A Postoperative Nomogram for Local Recurrence Risk in Extremity Soft Tissue Sarcomas After Limb-Sparing Surgery Without Adjuvant RadiationAnnals of Surgery, 255
R. Lindberg, R. Martin, M. Romsdahl, H. Barkley (1981)
Conservative surgery and postoperative radiotherapy in 300 adults with soft‐tissue sarcomasCancer, 47
P. Pautier, A. Floquet, N. Penel, S. Piperno-Neumann, N. Isambert, A. Rey, E. Bompas, A. Cioffi, C. Delcambre, D. Cupissol, F. Collin, J. Blay, M. Jimenez, F. Duffaud (2012)
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).The oncologist, 17 9
T. Brodowicz, R. Kotz, C. Wiltschke, C. Zielinski, P. Ritschl (1997)
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 5
I. Judson, John Radford, Maggie Harris, J. Blay, Q. Hoesel, A. Cesne, A. Oosterom, Mark Clemons, Claus Kamby, Cédric Hermans, J. Whittaker, E. Paola, J. Verweij, S. Nielsen (2001)
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.European journal of cancer, 37 7
(O’Sullivan B, Davis AM, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative versus postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2004;22(14 suppl):9007.)
O’Sullivan B, Davis AM, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative versus postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2004;22(14 suppl):9007.O’Sullivan B, Davis AM, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative versus postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2004;22(14 suppl):9007., O’Sullivan B, Davis AM, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative versus postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2004;22(14 suppl):9007.
J. Hartmann, K. Oechsle, J. Huober, A. Jakob, M. Azemar, M. Horger, L. Kanz, C. Bokemeyer (2006)
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcomaInvestigational New Drugs, 24
J. Blay, M. Glabbeke, J. Verweij, A. Oosterom, A. Cesne, J. Oosterhuis, I. Judson, O. Nielsen (2003)
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy.European journal of cancer, 39 1
A. Cesne, E. Antoine, M. Spielmann, T. Chevalier, E. Brain, C. Toussaint, N. Janin, L. Kayitalire, F. Fontaine, J. Génin (1995)
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 7
Beahrs Oh (1984)
The American Joint Committee on Cancer.Bulletin of the American College of Surgeons, 69 9
A. Italiano, S. Mathoulin-Pélissier, A. Cesne, P. Terrier, S. Bonvalot, F. Collin, J. Michels, J. Blay, J. Coindre, B. Bui (2011)
Trends in survival for patients with metastatic soft‐tissue sarcomaCancer, 117
W. Tap, Robin Jones, B. Chmielowski, A. Elias, D. Adkins, B. Tine, M. Agulnik, M. Cooney, M. Livingston, G. Pennock, A. Qin, A. Shahir, R. Ilaria, Ilaria Conti, J. Cosaert, G. Schwartz (2015)
A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor {alpha} (PDGFR{alpha}) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).Journal of Clinical Oncology, 33
X. Muro, A. López-pousa, Javier Martín, J. Buesa, J. Martínez-Trufero, A. Casado, A. Poveda, J. Cruz, I. Bover, J. Maurel (2005)
A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcomaCancer, 104
(Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224(6):756.)
Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224(6):756.Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224(6):756., Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224(6):756.
A. Elias, L. Ryan, A. Sulkes, J. Collins, J. Aisner, K. Antman (1989)
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 9
P. Zucali, A. Bertuzzi, H. Parra, E. Campagnoli, V. Quagliuolo, A. Santoro (2008)
The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomasInvestigational New Drugs, 26
G. Rosen, C. Forscher, Susan Lowenbraun, F. Eilber, J. Eckardt, Carmack Holmes, Yao Fu (1994)
Synovial sarcoma. Uniform response of metastases to high dose ifosfamideCancer, 73
E. Borden, D. Amato, C. Rosenbaum, H. Enterline, M. Shiraki, R. Creech, H. Lerner, P. Carbone (1987)
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 5 6
(2015)
J Clin Oncol
(Edge SB, Byrd DR, Compton CC, et al. AJCC (American Joint Committee on Cancer). Cancer staging manual. 7th ed. New York: Springer; 2010, p 291.)
Edge SB, Byrd DR, Compton CC, et al. AJCC (American Joint Committee on Cancer). Cancer staging manual. 7th ed. New York: Springer; 2010, p 291.Edge SB, Byrd DR, Compton CC, et al. AJCC (American Joint Committee on Cancer). Cancer staging manual. 7th ed. New York: Springer; 2010, p 291., Edge SB, Byrd DR, Compton CC, et al. AJCC (American Joint Committee on Cancer). Cancer staging manual. 7th ed. New York: Springer; 2010, p 291.
U. Maduekwe, F. Hornicek, D. Springfield, K. Raskin, D. Harmon, E. Choy, A. Rosenberg, G. Nielsen, T. Delaney, Yen-Lin Chen, M. Ott, Sam Yoon (2009)
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell SarcomasAnnals of Surgical Oncology, 16
(The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–iii112.)
The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–iii112.The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–iii112., The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–iii112.
A. Cesne, M. Ouali, M. Leahy, A. Santoro, H. Hoekstra, P. Hohenberger, F. Coevorden, P. Rutkowski, R. Hoesel, J. Verweij, S. Bonvalot, W. Steward, A. Gronchi, P. Hogendoorn, S. Litière, S. Marréaud, J. Blay, W. Graaf (2014)
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.Annals of oncology : official journal of the European Society for Medical Oncology, 25 12
(Demetri GD, Mehren VM, Jones RL, et al. A randomized phase III study of trabectidin or dacarbazin for the treatment of patients with advanced liposarcoma or leiomyosarcoma. J Clin Oncol. 2015;33(suppl):10503.)
Demetri GD, Mehren VM, Jones RL, et al. A randomized phase III study of trabectidin or dacarbazin for the treatment of patients with advanced liposarcoma or leiomyosarcoma. J Clin Oncol. 2015;33(suppl):10503.Demetri GD, Mehren VM, Jones RL, et al. A randomized phase III study of trabectidin or dacarbazin for the treatment of patients with advanced liposarcoma or leiomyosarcoma. J Clin Oncol. 2015;33(suppl):10503., Demetri GD, Mehren VM, Jones RL, et al. A randomized phase III study of trabectidin or dacarbazin for the treatment of patients with advanced liposarcoma or leiomyosarcoma. J Clin Oncol. 2015;33(suppl):10503.
P. Pisters, R. Pollock, Valerae Lewis, A. Yasko, J. Cormier, Paula Respondek, B. Feig, K. Hunt, P. Lin, G. Zagars, Caimiao Wei, M. Ballo (2007)
Long-term Results of Prospective Trial of Surgery Alone With Selective Use of Radiation for Patients With T1 Extremity and Trunk Soft Tissue SarcomasAnnals of Surgery, 246
S. Kummar, D. Allen, A. Monks, Eric Polley, C. Hose, S. Ivy, I. Turkbey, S. Lawrence, R. Kinders, P. Choyke, R. Simon, Seth Steinberg, J. Doroshow, L. Helman (2013)
Cediranib for metastatic alveolar soft part sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 18
D. Grunhagen, J. Wilt, W. Graveland, C. Verhoef, A. Geel, A. Eggermont (2006)
Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor‐α and melphalan for limb‐threatening soft tissue sarcomaCancer, 106
(Tap WD, Jones RL, Chmielowski B, et al. A randomized phase Ib/II study evaluating safety and efficacy of olaratumab (IMC-303) a human anti.platelet derived growth factor a (PDGFRa) monoclonal antibody with or without doxorubicin in advanced STS. J Clin Oncol. 2015;33(suppl):10501.)
Tap WD, Jones RL, Chmielowski B, et al. A randomized phase Ib/II study evaluating safety and efficacy of olaratumab (IMC-303) a human anti.platelet derived growth factor a (PDGFRa) monoclonal antibody with or without doxorubicin in advanced STS. J Clin Oncol. 2015;33(suppl):10501.Tap WD, Jones RL, Chmielowski B, et al. A randomized phase Ib/II study evaluating safety and efficacy of olaratumab (IMC-303) a human anti.platelet derived growth factor a (PDGFRa) monoclonal antibody with or without doxorubicin in advanced STS. J Clin Oncol. 2015;33(suppl):10501., Tap WD, Jones RL, Chmielowski B, et al. A randomized phase Ib/II study evaluating safety and efficacy of olaratumab (IMC-303) a human anti.platelet derived growth factor a (PDGFRa) monoclonal antibody with or without doxorubicin in advanced STS. J Clin Oncol. 2015;33(suppl):10501.
S. Rosenberg, J. Tepper, E. Glatstein, J. Costa, R. Young, A. Baker, M. Brennan, E. Demoss, C. Seipp, W. Sindelar, P. Sugarbaker, R. Wesley (1983)
Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremitiesCancer, 52
P. Pisters, L. Harrison, D. Leung, J. Woodruff, E. Casper, M. Brennan (1996)
Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 3
K. Antman, J. Crowley, S. Balcerzak, S. Rivkin, G. Weiss, A. Elias, R. Natale, R. Cooper, B. Barlogie, D. Trump (1993)
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 7
PhD MD, D. Grünhagen, PhD MD, PhD MD, PhD MD (2005)
Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated LimbsAnnals of Surgical Oncology, 12
M. Gutman, M. Inbar, D. Lev‐Shlush, Subhi Abu‐Abid, M. Mozes, S. Chaitchik, I. Meller, J. Klausner (1997)
High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservationCancer, 79
M. Tascilar, W. Loos, C. Seynaeve, J. Verweij, S. Sleijfer (2007)
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.The oncologist, 12 11
(Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma, Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73(10):2506–11.)
Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma, Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73(10):2506–11.Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma, Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73(10):2506–11., Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma, Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73(10):2506–11.
V. Bramwell, Dale Anderson, M. Charette (2000)
Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft-Tissue Sarcoma: A Meta-Analysis and Clinical Practice GuidelineSarcoma, 4
(2003)
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients
M. Angele, M. Albertsmeier, N. Prix, P. Hohenberger, S. Abdel-Rahman, N. Dieterle, Michael Schmidt, U. Mansmann, C. Bruns, R. Issels, K. Jauch, L. Lindner (2014)
Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection: A Subgroup Analysis of a Randomized Phase-III Multicenter StudyAnnals of Surgery, 260
A. Wagner, Izabela Malinowska-Kołodziej, J. Morgan, W. Qin, C. Fletcher, Natalie Vena, A. Ligon, C. Antonescu, N. Ramaiya, G. Demetri, D. Kwiatkowski, R. Maki (2010)
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 5
J. Tierney, R. Sylvester (1997)
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual dataThe Lancet, 350
J. Coindre, P. Terrier, Bui Nb, F. Bonichon, F. Collin, V. Doussal, Mandard Am, M. Vilain, J. Jacquemier, H. Duplay, X. Sastre, C. Barlier, M. Henry-Amar, J. Mace-Lesech, G. Contesso (1996)
Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 3
S. Stacchiotti, T. Negri, E. Palassini, E. Conca, A. Gronchi, C. Morosi, A. Messina, U. Pastorino, M. Pierotti, P. Casali, S. Pilotti (2010)
Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor ResponseMolecular Cancer Therapeutics, 9
D. Grunhagen, J. Wilt, W. Graveland, C. Verhoef, A. Geel, A. Eggermont (2006)
Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.Cancer, 106 8
N. Penel, B. Bui, J. Bay, D. Cupissol, I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, C. Fournier, S. Taieb, M. Jimenez, N. Isambert, F. Peyrade, C. Chevreau, E. Bompas, E. Brain, J. Blay (2008)
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 32
B. O'Sullivan, A. Davis, R. Turcotte, R. Bell, J. Wunder, C. Catton, R. Kandel, A. Sadura, D. Tu, J. Pater (2004)
Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
R. Maki, J. Wathen, Shreyaskumar Patel, D. Priebat, S. Okuno, B. Samuels, M. Fanucchi, D. Harmon, S. Schuetze, D. Reinke, P. Thall, R. Benjamin, L. Baker, M. Hensley (2007)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomasJournal of Clinical Oncology, 25
P. Pisters, D. Leung, J. Woodruff, W. Shi, M. Brennan (1996)
Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 5
J. Levay, B. O'Sullivan, C. Catton, R. Bell, V. Fornasier, B. Cummings, D. Hao, D. Warr, I. Quirt (1993)
Outcome and prognostic factors in soft tissue sarcoma in the adult.International journal of radiation oncology, biology, physics, 27 5
M. Endo, T. Nielsen (2012)
Pazopanib for metastatic soft-tissue sarcomaThe Lancet, 380
(Fletcher CDM, Bridge JA, Hogendoorn PCW, Lyon MF. World Health Organization classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.)
Fletcher CDM, Bridge JA, Hogendoorn PCW, Lyon MF. World Health Organization classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.Fletcher CDM, Bridge JA, Hogendoorn PCW, Lyon MF. World Health Organization classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013., Fletcher CDM, Bridge JA, Hogendoorn PCW, Lyon MF. World Health Organization classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.
F. Eilber, F. Eilber, J. Eckardt, G. Rosen, E. Riedel, R. Maki, M. Brennan, S. Singer (2004)
The Impact of Chemotherapy on the Survival of Patients With High-grade Primary Extremity LiposarcomaAnnals of Surgery, 240
V. Bramwell, M. Blackstein, K. Bélanger, S. Verma, S. Beare, E. Eisenhauer (1998)
A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue SarcomaSarcoma, 2
(Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC) Study 620. J Clin Oncol. 2009;27.)
Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC) Study 620. J Clin Oncol. 2009;27.Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC) Study 620. J Clin Oncol. 2009;27., Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC) Study 620. J Clin Oncol. 2009;27.
J. Martín-Liberal, S. Alam, A. Constantinidou, C. Fisher, K. Khabra, C. Messiou, D. Olmos, S. Mitchell, O. Al-Muderis, A. Miah, M. Linch, Robin Jones, M. Scurr, I. Judson, C. Benson (2013)
Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue SarcomaSarcoma, 2013
S. Sleijfer, I. Ray-Coquard, Z. Pápai, A. Cesne, M. Scurr, P. Schöffski, F. Collin, L. Pandite, S. Marréaud, A. Brauwer, M. Glabbeke, J. Verweij, J. Blay (2009)
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 19
R. Keus, E.J.Th. Rutgers, G. Ho, E. Gortzak, C. Albus‐Lutter, Augustinus Hart (1994)
Limb-sparing therapy of extremity soft tissue sarcomas: treatment outcome and long-term functional results.European journal of cancer, 30A 10
J. Gottlieb, Robert Benjamin, L. Baker, O'Bryan Rm, Joseph Sinkovics, B. Hoogstraten, Quagliana Jm, S. Rivkin, G. Bodey, Victorio Rodriguez, G. Blumenschein, Saiki Jh, C. Coltman, M. Burgess, P. Sullivan, T. Thigpen, R. Bottomley, S. Balcerzak, T. Moon (1976)
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.Cancer treatment reports, 60 2
E. Baldini, Joel Goldberg, C. Jenner, J. Manola, G. Demetri, C. Fletcher, S. Singer (1999)
Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 10
E. Gortzak, A. Azzarelli, J. Buesa, V. Bramwell, F. Coevorden, A. Geel, A. Ezzat, A. Santoro, J. Oosterhuis, M. Glabbeke, A. Kirkpatrick, J. Verweij (2001)
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.European journal of cancer, 37 9
J. Blay, A. Bertuzzi, S. Bielack, B. Bjerkehagen, S. Bonvalot, I. Boukovinas, P. Bruzzi, A. Tos, P. Dileo, M. Eriksson, A. Fedenko, A. Ferrari, S. Ferrari, H. Gelderblom, R. Grimer, A. Gronchi, R. Haas, K. Hall, P. Hohenberger, R. Issels, H. Joensuu, I. Judson, A. Cesne, S. Litière, J. Martín-Broto, O. Merimsky, M. Montemurro, C. Morosi, P. Picci, I. Ray-Coquard, P. Reichardt, P. Rutkowski, M. Schlemmer, S. Stacchiotti, Torri, A. Trama, F. Coevorden, W. Graaf, D. Vanel, E. Wardelmann, P. Casali (2015)
Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 25, pg iii102, 2014), 26
G. Zagars, M. Ballo, P. Pisters, R. Pollock, Shreyaskumar Patel, R. Benjamin (2003)
Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapyCancer, 97
E. Ewing (2012)
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 7
B. O'Sullivan, A. Davis, R. Turcotte, R. Bell, C. Catton, P. Chabot, J. Wunder, Rita Kandel, K. Goddard, A. Sadura, J. Pater, B. Zee (2002)
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trialThe Lancet, 359
B. Seddon, J. Whelan, S. Strauss, M. Leahy, P. Woll, F. Cowie, C. Rothermundt, Z. Wood, S. Forsyth, I. Khan, S. Nash, P. Patterson, S. Beare (2015)
GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29).Journal of Clinical Oncology, 33
D. Indelicato, Kenyon Meadows, C. Gibbs, C. Morris, M. Scarborough, R. Zlotecki (2009)
Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma.International journal of radiation oncology, biology, physics, 73 1
(Seddon BM, Whelan J, Strauss SJ, et al. GeDDis: a prospective randomized controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol. 2015;33(suppl):10500.)
Seddon BM, Whelan J, Strauss SJ, et al. GeDDis: a prospective randomized controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol. 2015;33(suppl):10500.Seddon BM, Whelan J, Strauss SJ, et al. GeDDis: a prospective randomized controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol. 2015;33(suppl):10500., Seddon BM, Whelan J, Strauss SJ, et al. GeDDis: a prospective randomized controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). J Clin Oncol. 2015;33(suppl):10500.
R. Siegel, K. Miller, A. Jemal (2015)
Cancer statistics, 2015CA: A Cancer Journal for Clinicians, 65
P. Gustafson, Karsten Dreinhöfer, A. Rydholm (1994)
Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients.Acta orthopaedica Scandinavica, 65 1
X Garcia del Muro, A Lopez-Pousa, J Martin (2005)
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on SarcomasCancer, 104
E. Noorda, B. Vrouenraets, O. Nieweg, F. Coevorden, G. Slooten, B. Kroon (2003)
Isolated limb perfusion with tumor necrosis factor‐α and melphalan for patients with unresectable soft tissue sarcoma of the extremitiesCancer, 98
W. Graaf, J. Blay, S. Chawla, Dong-Wan Kim, B. Bui-Nguyen, P. Casali, P. Schöffski, M. Aglietta, A. Staddon, Y. Beppu, A. Cesne, H. Gelderblom, I. Judson, N. Araki, M. Ouali, S. Marréaud, R. Hodge, Mohammed Dewji, C. Coens, G. Demetri, C. Fletcher, A. Tos, P. Hohenberger (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 379
S. Rosenberg, J. Tepper, E. Glatstein, J. Costa, A. Baker, Murray Brennam, E. Demoss, C. Seipp, W. Sindelar, P. Sugarbaker, R. Wesley (1982)
The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.Annals of surgery, 196 3
M. Schlemmer, P. Reichardt, J. Verweij, J. Hartmann, I. Judson, A. Thyss, P. Hogendoorn, S. Marréaud, M. Glabbeke, J. Blay (2008)
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.European journal of cancer, 44 16
Robin Jones, C. Fisher, O. Al-Muderis, I. Judson (2005)
Differential sensitivity of liposarcoma subtypes to chemotherapy.European journal of cancer, 41 18
D. Pearlstone, N. Janjan, B. Feig, A. Yasko, Kelly Hunt, Raphael Pollock, A. Lawyer, John Horton, P. Pisters (1999)
Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field.The cancer journal from Scientific American, 5 1
TF Delaney, DC Harmon, MC Gebhardt (2015)
Up ToDate
J. Yang, A. Chang, A. Baker, W. Sindelar, D. Danforth, S. Topalian, T. Delaney, E. Glatstein, S. Steinberg, Maria Merino, S. Rosenberg (1998)
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 1
C. Karakousis, D. Driscoll (1999)
Treatment and local control of primary extremity soft tissue sarcomasJournal of Surgical Oncology, 71
AJCC American Joint Committee on Cancer
S. Toma, G. Canavese, A. Grimaldi, G. Ravera, D. Ugolini, P. Percivale, F. Badellino (2003)
Concomitant chemo-radiotherapy in the treatment of locally advanced and/or metastatic soft tissue sarcomas: experience of the National Cancer Institute of Genoa.Oncology reports, 10 3
A. Ferrari, A. Gronchi, M. Casanova, C. Meazza, L. Gandola, P. Collini, L. Lozza, R. Bertulli, P. Olmi, P. Casali (2004)
Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institutionCancer, 101
S Sleijfer, M Ouali, M Glabbeke (2010)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for ResearchEur J Cancer, 46
B. Kasper, S. Sleijfer, S. Litière, S. Marréaud, J. Verweij, R. Hodge, S. Bauer, J. Kerst, W. Graaf (2014)
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.Annals of oncology : official journal of the European Society for Medical Oncology, 25 3
Y. Fong, D. Coit, J. Woodruff, M. Brennan (1993)
Lymph Node Metastasis From Soft Tissue Sarcoma in Adults Analysis of Data From a Prospective Database of 1772 Sarcoma PatientsAnnals of Surgery, 217
R. Maki, A. Italiano, H. Gelderblom, G. Grignani, V. Camargo, S. Bauer, S. Rha, S. Chawla, J. Blay, P. Hohenberger, D. D’Adamo, Benjamin Wang, B. Chmielowski, A. Cesne, G. Demetri, Shreyaskumar Patel (2015)
Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 18_suppl
J. Graham-Pole (1994)
Phase II TrialAnnals of Internal Medicine, 120
P. Lorigan, J. Verweij, Z. Pápai, S. Rodenhuis, A. Cesne, M. Leahy, J. Radford, M. Glabbeke, A. Kirkpatrick, P. Hogendoorn, J. Blay (2007)
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 21
O. Mir, T. Brodowicz, J. Wallet, A. Italiano, A. Cesne, J. Blay, T. Ryckewaert, F. Bertucci, S. Piperno-Neumann, F. Ploner, M. Toulmonde, J. Dômont, E. Saâda, C. Delcambre, N. Isambert, S. Delaine, S. Taïeb, E. Lindner, Bernadette Lieg-Atzwanger, N. Penel (2015)
Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial.Journal of Clinical Oncology, 33
(Martin-Liberal J, Alam S, Constantinidou A, et al. Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma. 2013;868–973.)
Martin-Liberal J, Alam S, Constantinidou A, et al. Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma. 2013;868–973.Martin-Liberal J, Alam S, Constantinidou A, et al. Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma. 2013;868–973., Martin-Liberal J, Alam S, Constantinidou A, et al. Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma. 2013;868–973.
(Mir O, Brodowicz T, Wallet J, et al. Activity of regorafenib in leimyosarcomas and other types of soft tissue sarcomas: results of double- blind, randomized placebo controlled phase II trial. J Clin Oncol. 2015;33(suppl):10504.)
Mir O, Brodowicz T, Wallet J, et al. Activity of regorafenib in leimyosarcomas and other types of soft tissue sarcomas: results of double- blind, randomized placebo controlled phase II trial. J Clin Oncol. 2015;33(suppl):10504.Mir O, Brodowicz T, Wallet J, et al. Activity of regorafenib in leimyosarcomas and other types of soft tissue sarcomas: results of double- blind, randomized placebo controlled phase II trial. J Clin Oncol. 2015;33(suppl):10504., Mir O, Brodowicz T, Wallet J, et al. Activity of regorafenib in leimyosarcomas and other types of soft tissue sarcomas: results of double- blind, randomized placebo controlled phase II trial. J Clin Oncol. 2015;33(suppl):10504.
V. Jo, L. Doyle (2016)
Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone.Surgical oncology clinics of North America, 25 4
(National Comprehensive Cancer Network. Soft tissue sarcoma (Version 1. 2015). http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed 15 May 2015.)
National Comprehensive Cancer Network. Soft tissue sarcoma (Version 1. 2015). http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed 15 May 2015.National Comprehensive Cancer Network. Soft tissue sarcoma (Version 1. 2015). http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed 15 May 2015., National Comprehensive Cancer Network. Soft tissue sarcoma (Version 1. 2015). http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed 15 May 2015.
G. Demetri, S. Chawla, M. Mehren, P. Ritch, L. Baker, J. Blay, K. Hande, M. Keohan, B. Samuels, S. Schuetze, C. Lebedinsky, Y. Elsayed, M. Izquierdo, Javier Gómez, Y. Park, A. Cesne (2009)
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 25
Shreyaskumar Patel, S. Vadhan-Raj, N. Papadopolous, C. Plager, M. Burgess, C. Hays, R. Benjamin (1997)
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 6
D. Andreou, H. Boldt, M. Werner, C. Hamann, D. Pink, P. Tunn (2013)
Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread--results of a large prospective trial.Annals of oncology : official journal of the European Society for Medical Oncology, 24 5
S. Stacchiotti, E. Palassini, R. Sanfilippo, B. Vincenzi, M. Arena, A. Bochicchio, P. Rosa, A. Nuzzo, S. Turano, C. Morosi, A. Tos, S. Pilotti, P. Casali (2012)
Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.Annals of oncology : official journal of the European Society for Medical Oncology, 23 2
G. Demetri, M. Mehren, Robin Jones, M. Hensley, S. Schuetze, A. Staddon, M. Milhem, A. Elias, K. Ganjoo, H. Tawbi, B. Tine, A. Spira, A. Dean, N. Khokhar, Y. Park, R. Knoblauch, T. Parekh, R. Maki, Shreyaskumar Patel (2015)
A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).Journal of Clinical Oncology, 33
P. Schöffski, I. Ray-Coquard, A. Cioffi, N. Bui, S. Bauer, J. Hartmann, A. Krarup-Hansen, V. Grünwald, R. Sciot, H. Dumez, J. Blay, A. Cesne, J. Wanders, C. Hayward, S. Marréaud, M. Ouali, P. Hohenberger (2011)
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.The Lancet. Oncology, 12 11
K. Billingsley, M. Burt, Ellen Jara, R. Ginsberg, J. Woodruff, D. Leung, M. Brennan (1999)
Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival.Annals of surgery, 229 5
P. Pisters, Shreyaskumar Patel, V. Prieto, P. Thall, Valerae Lewis, B. Feig, K. Hunt, A. Yasko, P. Lin, M. Jacobson, M. Burgess, R. Pollock, G. Zagars, R. Benjamin, M. Ballo (2004)
Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 16
(Schöffski P, Maki RG, Italiano A, et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma. J Clin Oncol. 2015;33(18 suppl):LBA10502.)
Schöffski P, Maki RG, Italiano A, et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma. J Clin Oncol. 2015;33(18 suppl):LBA10502.Schöffski P, Maki RG, Italiano A, et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma. J Clin Oncol. 2015;33(18 suppl):LBA10502., Schöffski P, Maki RG, Italiano A, et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma. J Clin Oncol. 2015;33(18 suppl):LBA10502.
(Endo M, Nielsen TO. Pazopanib for metastatic soft-tissue sarcoma. Lancet. 2012;380(9844):801 (author reply 801).)
Endo M, Nielsen TO. Pazopanib for metastatic soft-tissue sarcoma. Lancet. 2012;380(9844):801 (author reply 801).Endo M, Nielsen TO. Pazopanib for metastatic soft-tissue sarcoma. Lancet. 2012;380(9844):801 (author reply 801)., Endo M, Nielsen TO. Pazopanib for metastatic soft-tissue sarcoma. Lancet. 2012;380(9844):801 (author reply 801).
JN Cormier, SR Patel, CE Herzog (2001)
Concurrent ifisfamide-based chemotherapy and irradiation. Analysis of treatment related toxicity in 43 patients with sarcomaCancer, 92
G. Burton, C. Rankin, M. Zalupski, G. Mills, E. Borden, Antman Karen (2006)
Phase II Trial of Gemcitabine as First Line Chemotherapy in Patients With Metastatic or Unresectable Soft Tissue SarcomaAmerican Journal of Clinical Oncology, 29
X. Garcia-Del-Muro, A. López-pousa, J. Maurel, Javier Martín, J. Martínez-Trufero, A. Casado, A. Gómez-España, J. Fra, J. Cruz, A. Poveda, A. Meana, C. Pericay, R. Cubedo, J. Rubió, A. Juan, N. Laínez, J. Carrasco, R. Andrés, J. Buesa (2011)
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 18
(van der Graaf WT, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2012;379:1879–86.)
van der Graaf WT, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2012;379:1879–86.van der Graaf WT, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2012;379:1879–86., van der Graaf WT, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2012;379:1879–86.
S. Sleijfer, M. Ouali, M. Glabbeke, A. Krarup-Hansen, S. Rodenhuis, A. Cesne, P. Hogendoorn, J. Verweij, J. Blay (2010)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone SarcomEuropean journal of cancer, 46 1
A. Jemal, R. Tiwari, Taylor Murray, Asma Ghafoor, A. Samuels, Elizabeth Ward, E. Feuer, M. Thun (2004)
Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 54
I. Judson, J. Verweij, H. Gelderblom, J. Hartmann, P. Schöffski, J. Blay, J. Kerst, J. Šufliarsky, J. Whelan, P. Hohenberger, A. Krarup-Hansen, T. Alcindor, T. Alcindor, S. Marréaud, S. Litière, Catherine Hermans, C. Fisher, P. Hogendoorn, A. Tos, W. Graaf (2014)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.The Lancet. Oncology, 15 4
A. Eggermont, H. Koops, J. Klausner, B. Kroon, P. Schlag, D. Liénard, A. Geel, H. Hoekstra, I. Meller, O. Nieweg, C. Kettelhack, G. Ben‐Ari, J. Pector, F. Lejeune (1996)
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.Annals of surgery, 224 6
R. Issels, L. Lindner, J. Verweij, P. Wust, P. Reichardt, B. Schem, S. Abdel-Rahman, S. Daugaard, C. Salat, C. Wendtner, Ž. Vujašković, R. Wessalowski, K. Jauch, H. Dürr, F. Ploner, A. Baur‐Melnyk, U. Mansmann, W. Hiddemann, J. Blay, P. Hohenberger (2010)
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.The Lancet. Oncology, 11 6
D. Goldstein, B. Cheuvart, D. Trump, M. Shiraki, R. Comis, D. Tormey, J. Harris, E. Borden (1990)
Phase II Trial of Carboplatin in Soft‐Tissue SarcomaAmerican Journal of Clinical Oncology, 13
Sarcomas are uncommon malignancies accounting for about 1% of all adult malignancies. Sarcomas are a heterogeneous group of tumors which includes more than 100 different subtypes. Surgery is the mainstay therapy for localized disease. In selected patients the combination of surgery with radiotherapy achieves better local control and offers the best chance of cure. Systemic treatment including cytotoxic chemotherapy or targeted therapies remains the mainstay therapy for most patients with advanced disease. There are a wide variety of clinical situations, such that an individualized treatment plan must be defined by a multidisciplinary tumor board. Treatment decisions should take into consideration the histology, site of disease, stage, performance status, treatment goals, and the patient’s wishes. The management of patients should be carried out in a center with expertise in the treatment of sarcomas for optimal outcome. This review will cover the different treatment modalities of adult soft tissue sarcomas.
Oncology and Therapy – Springer Journals
Published: Sep 7, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.